At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 78 target
Drug / intervention
EVM16 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors
In Brief
A Phase 1 clinical trial evaluating EVM16 and Tislelizumab for Advanced or Recurrent Solid Tumors. Currently recruiting, targeting 78 participants across 2 sites.
Signals
Enrolling ahead of pace
Detailed Summary
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment. The main questions to answer are: Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Recurrent Solid Tumors
CountriesChina
CollaboratorsShanghai Cancer Centre, Everest Medicines (China) Co.,Ltd.
Timeline
Phase 1Recruiting
20252026202720282029
First PostedAug 2024
Enrollment StartMar 2025
TodayJul 2026
Primary CompletionMar 2028
Study CompletionDec 2028
First PostedAug 7, 2024
Enrollment StartMar 4, 2025
Primary CompletionMar 1, 2028
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 3.0 yearsPosted 1.9 years agoPrimary completion in 1.7 years
Interventions
EVM16biological
cancer vaccine
Tislelizumabdrug
Anti-PD1 antibody